This experimental report investigates the efficacy of melatonin in managing metabolic syndrome. The study utilized a randomized, placebo-controlled design involving Sprague-Dawley rats induced with metabolic syndrome via a high-fat diet. Rats were treated with melatonin for four weeks, and blood samples were collected to measure glucose, insulin, total cholesterol, and triglycerides. The results, analyzed using ANOVA, revealed that melatonin significantly reduced insulin and triglycerides compared to the control group. The report includes detailed methods, materials, and a discussion of the findings in relation to existing literature. The study concludes that melatonin demonstrates positive effects on metabolic syndrome management by lowering insulin and triglyceride levels, suggesting its potential as a therapeutic intervention. Limitations include the lack of gender-specific analysis. The study provides valuable insights into the pharmacological effects of melatonin in the context of metabolic disorders.